U.K. unveils cancer vaccine program, deal with BioNTech to improve patient access
Initiative part of push to improve clinical trial participation
The U.K. is hoping to revitalize its status as a preferred destination for clinical trials via the launch of a cancer vaccines trial initiative and a partnership with BioNTech to enroll up to 10,000 cancer patients in new studies.
NHS England and Genomics England jointly announced the launch of the Cancer Vaccine Launch Pad, an initiative that aims to improve access for U.K. patients to personalized cancer vaccines. The program’s first major partner, BioNTech SE (NASDAQ:BNTX), will test its mRNA-based cancer vaccines in U.K.-based clinical trials. As part of the deal, BioNTech will establish an R&D hub in Cambridge. BioNTech first announced its intention in January to provide up to 10,000 U.K. cancer patients with personalized immunotherapies by 2030...